CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Open Label, Single-Arm Study of Cabozantinib in Combination With Pembrolizumab in the Treatment of Locally Advanced or Metastatic Adrenocortical Carcinoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06006013
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:24.052096+00:00
Published At: 2026-02-18T00:00:00+00:00
Record Updated At: 2026-02-18
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Locally Advanced Adrenal Cortex Carcinoma", "Adrenal Cortical Carcinoma", "Stage III Adrenal Cortex Carcinoma", "Stage IV Adrenal Cortex Carcinoma AJCC v8", "Unresectable Adrenal Cortex Carcinoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-02-18"
protocolSection.identificationModule.nctId: "NCT06006013"
protocolSection.identificationModule.officialTitle: "Phase II Open Label, Single-Arm Study of Cabozantinib in Combination With Pembrolizumab in the Treatment of Locally Advanced or Metastatic Adrenocortical Carcinoma"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.